CFR Chemaphor Inc.

Further to its press release dated June 21, 2010, announcing the acquisition of
rights to a new stem cell regenerative treatment for animals in Canada,
Chemaphor Inc. (TSX VENTURE:CFR) announced today that Amin Khalifa has agreed to
join Chemaphor's board of directors in the role of Co-Chair. In addition, Amin
has signed a consulting agreement, under which Amin will assist Chemaphor with
overall commercial plans, implementing sales strategies and connecting Chemaphor
with other, commercially focused groups that are relevant to Chemaphor's growth
strategy. Amin will share the role of Co-Chair with David Hankinson.


Mr. Khalifa currently sits on the Board of Directors of PetSmart, Inc.
(Nasdaq:PETM) and has been the CFO of several public companies, including
divisions of Monsanto, Aetna and Pepsico. He has extensive investment banking
experience and has been actively involved in corporate and business development
activity, having acted as principal in several large acquisitions. 


Amin's prior experience includes:



--  CFO and EVP at Apria Healthcare Group, Inc. for three years, where he
    identified and closed nearly one hundred acquisitions. Apria was
    purchased by a private equity firm, The Blackstone Group L.P., for $1.7B
    in 2008. 
    
--  VP and CFO of Beckman Coulter (NYSE:BEC). 
    
--  Positions held at Monsanto (NYSE:MON) as Chief Financial Officer of the
    Agricultural Sector, as well as a Senior Vice President of Strategy and
    Investor Relations for Aetna Inc. (NYSE:AET) and CFO of Aetna Health
    Plans. Amin also previously worked as CFO and in business development
    capacities during his fifteen year tenure at PepsiCo (NYSE:PEP). 
    



David Hankinson, Co-Chair of Chemaphor, commented, "Having recently completed
our first acquisition that confirms our focus on commercial opportunities within
the animal health sector, we are delighted to attract to Chemaphor someone of
Amin's very high caliber. Amin adds commercial, financial, corporate and
business development experience, while having a specific understanding of our
target markets. We welcome him to the board as Co-Chair and look forward to
growing the company, together."


Mr. Khalifa added, "I have been fortunate to contribute to and experience growth
from within large organizations and have had success. I have a strong interest
in animal health and am convinced that I can translate the knowledge and
experiences from the larger companies into successful growth at Chemaphor. I
have reviewed Chemaphor's pipeline of opportunities and think that we have found
a great fit."


The appointment of Mr. Khalifa, as with any director, remains subject to
regulatory approval, including approval of the TSX Venture Exchange.


About Chemaphor

Chemaphor. a wellness company. is committed to developing and delivering natural
health enhancer ("NHE") products to humans and animals to assist in optimizing
health and daily quality of life. Chemaphor is advancing NHE product candidates
for the food animal market, companion animal market and various, potential human
applications. More information can be found at www.chemaphor.com.


Forward Looking Statements

This press release contains forward-looking statements regarding, among other
things, Chemaphor's beliefs, plans, objectives, strategies, estimates,
intentions and expectations. Actual results and events may differ materially
from those included in, contemplated or implied by such forward looking
statements for a variety of reasons. When used in this press release, the words
"seek", "believe", "develop", "intends", "will", "may", "potential", "should"
and similar expressions are intended to be among the statements that identify
forward-looking statements. Forward-looking statements are subject to inherent
risks and uncertainties including, but not limited to, market and general
economic conditions, the availability to attract and retain key personnel, the
availability and terms of financing, the scientific and commercial viability of
planned products, changes in Chemaphor's relationship with its key suppliers and
partners, competitive factors, changes in regulatory environments affecting
Chemaphor's business, and the accuracy in management's assumptions. This list is
not exhaustive of the factors that may affect any of Chemaphor's forward-looking
statements. Investors and others should carefully consider these and other
factors and not place undue reliance on these forward-looking statements. In
addition, these forward-looking statements relate to the date on which they were
made and Chemaphor disclaims and has no intention or obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise.

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024